Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
Troppmann
C
C
Department of Surgery, University of Minnesota, Minneapolis.
Almond
P S
PS
Payne
W D
WD
Dunn
D L
DL
Gores
P F
PF
Gruessner
R W
RW
Sutherland
D E
DE
Matas
A J
AJ
Najarian
J S
JS
D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology / Q000503:physiopathology* / Q000628:therapy; D006085:Graft Survival / Q000276:immunology / Q000502:physiology*; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D007683:Kidney Tubular Necrosis, Acute / Q000503:physiopathology*; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D013997:Time Factors; D014019:Tissue Donors; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone